Advertisement
Home »

Q&A: Using Effective Treatments Earlier for NSCLC

Jan 01, 2024

REFERENCES & ADDITIONAL READING

Herbst R, et al. Optimizing Resectable NSCLC Outcomes in Patients With Actionable Mutations. ESMO Congress 2023; October 20-24, 2023: Madrid.

ABOUT THE CONTRIBUTORS

  • Roy S. Herbst, MD, PhD

    Deputy Director
    Yale Cancer Center
    Assistant Dean for Translational Research
    Yale School of Medicine

Advertisement

MEETING BRIEFS

Advertisement